Cymat Technologies (CYM) AI Stock Analysis

• Market Cap: C$12.04M
• Dividend Yield: N/A
• Average Volume (3M): 118.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: -25.74%
• EPS Growth: 2.28%
• Country: CA
• Employees: 11
• Sector: General
• Sector Strength: N/A
• Industry: Manufacturing - Metal Fabrication
• EPS (TTM): -0.01
• Shares Outstanding: 100,371,750
• 10 Day Avg. Volume: 20,030
• 30 Day Avg. Volume: 118,582
• PEG Ratio: 0.12
• Price to Book (P/B): -2.03
• Price to Sales (P/S): 2.58
• P/FCF Ratio: -5.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: C$0.11 ▼(-9.17% Downside)

The score is primarily constrained by very weak financial performance (deep losses, cash burn, and a stressed balance sheet with negative equity). Technicals are only neutral and do not offset the fundamental risk, while valuation remains pressured due to negative earnings and no indicated dividend yield support.

Positive Factors

Innovative Product Offering

Cymat's proprietary Alusion® material offers unique solutions in multiple industries, potentially driving long-term demand and market differentiation.

Strategic Partnerships

Strategic partnerships can expand Cymat's market presence and product development, supporting sustainable revenue growth and competitive positioning.

Secondary Revenue Stream

Licensing offers a stable revenue stream, reducing reliance on direct sales and enhancing financial resilience through diversified income sources.

Negative Factors

Declining Revenue

Declining revenue growth indicates potential market challenges and operational inefficiencies, impacting long-term financial health and stability.

High Leverage

High leverage can strain financial resources, limiting flexibility and increasing risk, potentially affecting long-term operational capabilities.

Negative Profitability

Negative profitability reflects operational inefficiencies, which can hinder investment in growth initiatives and affect long-term business viability.

Cymat Technologies Business Overview & Revenue Model

Company Description

Cymat Technologies Ltd., a materials technology company, manufactures and sells stabilized aluminum foam products worldwide. The company provides architectural materials under the Alusion brand name; and automotive and blast mitigation products under the SmartMetal brand name. It serves defense and military, automotive and transportation, architectural, and other application. The company was incorporated in 2006 and is based in Mississauga, Canada.

How the Company Makes Money

Cymat Technologies generates revenue primarily through the sale of its Alusion® stabilized aluminum foam products to various industries, including construction, automotive, aerospace, and defense. The company capitalizes on its proprietary technology by licensing its manufacturing processes to partners, which provides a secondary revenue stream. Additionally, Cymat engages in strategic partnerships with companies within these sectors to enhance its market reach and product development, enabling it to secure contracts and expand its customer base. The company's earnings are also bolstered by ongoing research and development initiatives that aim to innovate and improve its product offerings, allowing it to meet the evolving needs of its clients.

Cymat Technologies Financial Statement Overview

Summary

Cymat Technologies is facing significant financial challenges across all major financial statements. The company is struggling with declining revenues, negative profitability, and high leverage. Cash flow issues persist despite some growth in free cash flow. Overall, the financial health of the company is concerning, with substantial risks due to operational inefficiencies and financial instability.

Income Statement

Cymat Technologies has faced significant challenges in its income statement metrics. The company has experienced declining revenue growth, with a negative growth rate in recent years. Profitability metrics such as gross profit margin and net profit margin are weak, indicating operational inefficiencies and high costs relative to revenue. The EBIT and EBITDA margins are also negative, reflecting ongoing operational losses.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity, indicating more liabilities than assets. The debt-to-equity ratio is negative, suggesting high leverage and financial instability. Return on equity is also negative, highlighting the company's inability to generate profits from shareholders' investments.

Cash Flow

Cash flow metrics show some improvement in free cash flow growth, but overall cash flow remains negative. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to net income. The free cash flow to net income ratio is slightly positive, suggesting some ability to cover net losses with free cash flow, but overall cash flow health is weak.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2021	Dec 2021
Income Statement
Total Revenue	3.71M	1.62M	3.05M	4.15M	3.12M
Gross Profit	494.39K	-412.85K	-270.42K	2.12M	795.48K
EBITDA	-1.91M	-3.34M	-5.45M	252.17K	-4.23M
Net Income	-3.37M	-4.27M	-6.05M	-543.00K	-4.75M
Balance Sheet
Total Assets	2.76M	3.96M	4.16M	6.58M	6.17M
Cash, Cash Equivalents and Short-Term Investments	354.03K	56.27K	324.05K	5.02M	2.47M
Total Debt	5.58M	2.94M	2.28M	1.38M	1.02M
Total Liabilities	7.49M	6.78M	4.77M	3.71M	3.83M
Stockholders Equity	-4.73M	-2.81M	-612.07K	2.88M	2.34M
Cash Flow
Free Cash Flow	-1.64M	-2.26M	-3.49M	401.48K	-4.53M
Operating Cash Flow	-1.60M	-2.23M	-2.46M	432.92K	-4.32M
Investing Cash Flow	-37.52K	-31.32K	-1.03M	-31.44K	-534.54K
Financing Cash Flow	1.93M	1.99M	1.18M	4.36M	2.30M

Cymat Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.12
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CYM, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.11, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.76 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:CYM.

Cymat Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DRX	73 Outperform	C$262.40M	9.12	16.89%	0.46%	-26.61%	-45.62%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
USCU	50 Neutral	C$26.24M	-22.50	-162.83%	―	―	1.23%
IB	46 Neutral	C$25.17M	-5.87	-78.49%	―	―	―
MTS	45 Neutral	C$14.55M	-9.27	-92.01%	―	―	―
CYM	40 Underperform	C$12.04M	-2.37	―	―	-25.74%	2.28%

Cymat Technologies Corporate Events

Cymat Technologies Secures $1.8M Military Order and Completes Equity Placement

Cymat Technologies Ltd. announced a $1.8 million order for its SmartMetal underbelly kits from an Asian military vehicle manufacturer, marking the third purchase order under the customer’s full-rate production schedule. This contract, expected to be worth $4M-$5M, aligns with global trends in defense spending, potentially enhancing sales opportunities for Cymat’s customer and increasing interest from other SmartMetal clients. Additionally, Cymat completed a non-brokered private placement of equity units, raising $1,551,500.

The most recent analyst rating on (TSE:CYM) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on Cymat Technologies stock, see the TSE:CYM Stock Forecast page.

Cymat Technologies Schedules Investor Update Call

Cymat Technologies Ltd. announced an investor update call scheduled for November 12, 2025, to provide stakeholders with updates on its ongoing projects and initiatives. This call is part of Cymat’s efforts to keep investors informed about its operations and strategic direction, potentially impacting its market position and stakeholder relations.

Cymat Technologies Announces Private Placement to Support Strategic Growth

Cymat Technologies has announced an update on its non-brokered private placement of equity Units, aiming to issue 11,934,615 Units for gross proceeds of $1,551,500. The proceeds will be used for capital equipment purchases and working capital to support a major strategic business development initiative. The offering is subject to TSX Venture Exchange approval and includes provisions to prevent the creation of new Insiders without necessary approvals. This move is expected to bolster Cymat’s operational capabilities and strategic positioning in its industry.